- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02309346
Clindamycin Once a Day in Septic Abortion (CLINDA-PRO)
A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion.
Septic abortion is a serious condition. Women with septic abortion are treated with clindamycin plus gentamicin using divided doses, i.e., thrice a day.
The objective of this study is to compare the rates of cure between once or thrice a day use of clindamycin with gentamicin in cases of septic abortion.
Study Overview
Detailed Description
Obstetric infections are very common, especially in developing countries, as a consequence of the practice of unsafe abortion. In these countries, an estimated five million women each year are hospitalized due to complications from induced abortions, which equates to a rate of 5-7 per thousand women.
Abortion remains a leading cause of maternal death in developing countries. According to the World Health Organization, it is estimated that 1 in 8 maternal deaths occur from complications of illegal abortion. Septic abortions play an important role in the maternal morbidity and mortality. The diagnosis of septic abortion should be considered when a woman of reproductive age presents with menstrual delay, vaginal bleeding accompanied by abdominal pain and fever.
In 1989, Plaisance et al. demonstrated that Clindamycin, an antibiotic used for septic abortion, could be prescribed at a dose of 12/12 hours, and bacterial inhibitory serum levels were similar to those in divided doses 6/6 hours. In 2003, Livingston et al. published the results of gentamicin and clindamycin combined in a single daily dose for cases of post-cesarean endometritis. Administration of clindamycin differed by being in a dose of 2700mg daily dose of different fractional 6/6 hours, or 8/8 hours, and the cure rates were 82% (45 of 56 cases successes) in a single daily dose (13). The etiology of postpartum endometritis is similar to that in infected abortion (14, 15), but little information exists regarding the use of single daily dose in this disease.
A retrospective study recently conducted by our group showed that patients with infected abortion treated with Clindamycin single dose achieved cure rates of 98% (95% CI - 95 to 99%), suggesting an equivalence between a single daily dose and treatment conventional three daily doses.
OBJECTIVES The objective of this study is to verify the equivalence of using Clindamycin once a day versus 3 times daily in the rates of cure of septic abortion.
Hypotheses H0: Ps> Pn+2 The percentage of clinical cure with standard treatment (Ps) is greater than the rate of cure of alternative treatment + 2%.
Ha: Ps - 2% ≤ Pn The percentage of clinical cure with traditional treatment (Ps) minus 2% is less than or equal to the percentage of cure alternative treatment (Pn).
Variables
- Standard treatment (Clindamycin 3x daily)
- Alternative treatment (1x daily Clindamycin)
- Clinical improvement (present or absent), defined as absence of fever (≤37.7 ° C), normal WBC (≤12.000 total leukocytes), eating and walking without difficulty, as already described in the literature.
Materials and methods Design Randomized, prospective, double-blind study with two arms that follow the parameters of the CONSORT (17).
Geographic and temporal limitations The study will be conducted in patients attending the emergency unit at HCPA. A period of 24 months for data collection (about 4 patients per month), it will be necessary to reach sample size.
Inclusion criteria
All patients who come to emergency unit at HCPA with clinical diagnosis of septic abortion and will be treated with Clindamycin will be invited. The diagnosis of infected abortion is the same as used previously described by our group (9). Briefly, the presence of one of the criteria below in a < 20 weeks gestation, associated with a suspected ovular infection:
- History of intrauterine manipulation with contaminated objects.
- Vaginal discharge with foul odor.
- Presence of pus flowing through the cervix.
- Signs of peritoneal irritation.
- leukocytosis (> 14,000 leukocytes / ml).
- Warm Extremities, thready pulse and tachycardia (HR> 110 bpm)
- Cyanosis and / or paleness
- Tachypnea (MR> 30mrpm)
- hypotension (Systolic Blood Pressure <90 mmHg)
- Oliguria
- Hyperthermia (≥ 37.8 ° C) Exclusion criteria
Will be excluded all patients who:
- Do not wish to participate in the project.
- They used antibiotics prior to hospitalization (1 week period).
- Being allergic to clindamycin or gentamicin. Execution Patients eligible for the study will be invited to participate in the study at hospital admission for uterine curettage. After reading and signing the informed consent, patients will answer a standardized interview and after the interview, she will be randomized.
Randomization Subjects will be randomly allocated to treatment with clindamycin 3 times a day, or once a day; random sequence will be generated by a computer grouped into blocks of 4 treatments. The randomization sequence will be obtained from sequential sealed envelope that will be in possession of the pharmacy emergency service HCPA. Researcher will not have access to the following treatment sequence. The Pharmacy Service will prepare the medication that will be part of routine emergency Gynecological Unit.
Patients and researchers will be blind to treatment allocation; saline infusion will be given in the place of clindamycin to keep patients blind to treatment arm.
Treatment
The regimen will consist of:
Standard treatment (Ps.): Clindamycin (900mg intravenously 8/8 hours diluted in 250 ml saline 0.9% solution (SF). The first vial of SF will contain 240 mg of gentamicin.
Alternative treatment (Pn): Clindamycin (2700mg) + gentamicin (240 mg) diluted in 250 ml of 0.9% saline. Two additional vials of SF 0.9% will be infused every 8 h as placebo.
The treatment will be continued up to 48 hours of good clinical condition, defined as absence of fever, decreased vaginal bleeding, minimal or no pain (AVS <4), leukocyte count within the normal range, evacuating and walking normally.
Follow-up All women included in the study will be reviewed within 7 days after discharge as routine at the gynecologic emergency unit, to receive the results of the pathology.
Outcomes
The following outcomes will be assessed:
- Clinical improvement until discharge in number of days of hospitalization, complications related to treatment.
- Treatment failure will be considered as persistence of fever (≥37.8ºC) during hospital admission, worsening of abdominal pain, persistent vaginal bleeding, need for exchange clindamycin due to treatment failure, or the need to add other antibiotics, either intravenously or orally.
- Hospital readmission within 7 days after discharge due to fever (Tax ≥37.8ºC), persistent pelvic pain, persistence or increase of uterine bleeding, or other hospital admission related to the septic abortion.
- Presence of urinary tract infection or candidiasis, persistence of ovular contents will not be considered as treatment failure.
Sample Size The sample size was calculated as a trial of non-inferiority, using the formula proposed in the literature (18). According to data obtained in a retrospective study by our group (16) we expect that the estimated rate of clinical cure is 99% (95% CI - 95 to 99%) in the group with three daily doses and 100% (95% CI - 99 to 100%) in the experimental treatment. For a non-inferiority study, using a power of 90%, an alpha error of 5% and a lower limit for non-inferiority of 2%, 95 cases will be needed in each group.
Statistical analysis Data will be analyzed by intention to treat and per protocol. The definition of intention to treat is based on the criteria suggested in the literature. The statistical analysis will be performed using Student t-test to compare the difference of means; chi-square test will be used to compare proportions with confidence intervals.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Daniel M da Silva, Phar
- Phone Number: +555133597542
- Email: danielmsilva@hcpa.edu.br
Study Contact Backup
- Name: Ernesto P Guedes neto, MD, PhD
- Phone Number: +555132211455
- Email: epgneto@gmail.com
Study Locations
-
-
Rio Grande Do Sul
-
Porto Alegre, Rio Grande Do Sul, Brazil, 90035-003
- Recruiting
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Ricardo F Savaris, MD, PhD
- Phone Number: 55 51 33598405
- Email: rsavaris@hcpa.edu.br
-
Principal Investigator:
- Ricardo F Savaris, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women with clinical diagnosis of septic abortion
Exclusion Criteria:
- Refuse to participate in the study
- Use of antibiotics with 1 week prior randomization
- Known allergy to clindamycin or gentamcin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: clindamycin once a day
Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v.
once a day until clinical improvement
|
Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v.
once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v.
8/8 h diluted in 250ml of sterile saline solution
|
Active Comparator: clindamycin thrice a day
Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v.
8/8 h diluted in 250ml of sterile saline solution
|
Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v.
once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v.
8/8 h diluted in 250ml of sterile saline solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cure (Clinical improvement defined as reduce of pain, bleeding and no fever for 48h)
Time Frame: 72 hours
|
Clinical improvement defined as reduce of pain, bleeding and no fever for 48h Treatment failure will be considered as persistence of fever (≥37.8ºC)
during hospital admission, worsening of abdominal pain, persistent vaginal bleeding, need for exchange clindamycin due to treatment failure, or the need to add other antibiotics, either intravenously or orally.
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complications (Return to the hospital for admission related to the evacuation procedure within 7 days)
Time Frame: 7 days
|
Return to the hospital for admission related to the evacuation procedure within 7 days
|
7 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ricardo F Savaris, MD, PhD, Federal University of Rio Grande do Sul
Publications and helpful links
General Publications
- Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999 Sep 11;319(7211):670-4. doi: 10.1136/bmj.319.7211.670.
- Stubblefield PG, Grimes DA. Septic abortion. N Engl J Med. 1994 Aug 4;331(5):310-4. doi: 10.1056/NEJM199408043310507.
- French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD001067. doi: 10.1002/14651858.CD001067.pub2.
- Grimes DA. The "CONSORT" guidelines for randomized controlled trials in Obstetrics & Gynecology. Obstet Gynecol. 2002 Oct;100(4):631-2. doi: 10.1016/s0029-7844(02)02233-0. No abstract available.
- Singh S. Hospital admissions resulting from unsafe abortion: estimates from 13 developing countries. Lancet. 2006 Nov 25;368(9550):1887-92. doi: 10.1016/S0140-6736(06)69778-X.
- Ahman E, Shah IH. New estimates and trends regarding unsafe abortion mortality. Int J Gynaecol Obstet. 2011 Nov;115(2):121-6. doi: 10.1016/j.ijgo.2011.05.027. Epub 2011 Aug 31.
- Del Priore G, Jackson-Stone M, Shim EK, Garfinkel J, Eichmann MA, Frederiksen MC. A comparison of once-daily and 8-hour gentamicin dosing in the treatment of postpartum endometritis. Obstet Gynecol. 1996 Jun;87(6):994-1000. doi: 10.1016/0029-7844(96)00054-3.
- Hemsell DL, Martens MG, Faro S, Gall S, McGregor JA. A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women. Clin Infect Dis. 1997 Feb;24 Suppl 2:S222-30. doi: 10.1093/clinids/24.supplement_2.s222.
- Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650-5. doi: 10.1128/AAC.39.3.650.
- Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD005091. doi: 10.1002/14651858.CD005091.pub3.
- Plaisance KI, Drusano GL, Forrest A, Townsend RJ, Standiford HC. Pharmacokinetic evaluation of two dosage regimens of clindamycin phosphate. Antimicrob Agents Chemother. 1989 May;33(5):618-20. doi: 10.1128/AAC.33.5.618.
- Livingston JC, Llata E, Rinehart E, Leidwanger C, Mabie B, Haddad B, Sibai B. Gentamicin and clindamycin therapy in postpartum endometritis: the efficacy of daily dosing versus dosing every 8 hours. Am J Obstet Gynecol. 2003 Jan;188(1):149-52. doi: 10.1067/mob.2003.88.
- Moberg PJ, Gottlieb C, Nord CE. Anaerobic bacteria in uterine infection following first trimester abortion. Eur J Clin Microbiol. 1982 Apr;1(2):82-6. doi: 10.1007/BF02014196.
- Soper DE. Postpartum endometritis. Pathophysiology and prevention. J Reprod Med. 1988 Jan;33(1 Suppl):97-100.
- Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials. 1982 Dec;3(4):345-53. doi: 10.1016/0197-2456(82)90024-1.
- Savaris RF, de Moraes GS, Cristovam RA, Braun RD. Are antibiotics necessary after 48 hours of improvement in infected/septic abortions? A randomized controlled trial followed by a cohort study. Am J Obstet Gynecol. 2011 Apr;204(4):301.e1-5. doi: 10.1016/j.ajog.2010.11.017. Epub 2010 Dec 31.
- Giugno CS, Silva AL, Fuhrich DG, Rabaioli PS, Goncalves KG, Sartor NC, Savaris RF. Daily dose of clindamycin versus standard divided doses in obstetrical and gynecological infections: a retrospective cohort study. Int J STD AIDS. 2013 Nov;24(11):893-8. doi: 10.1177/0956462413487516. Epub 2013 Jul 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Pregnancy Complications
- Abortion, Spontaneous
- Pregnancy Complications, Infectious
- Abortion, Septic
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Clindamycin
- Clindamycin palmitate
- Clindamycin phosphate
Other Study ID Numbers
- 14-0328
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Abortion
-
Hospital de Clinicas de Porto AlegreTerminated
-
Hospital de Clinicas de Porto AlegreTerminated
-
IpasSt. Paul's Hospital Millennium Medical College, Addis Ababa, EthiopiaCompletedMedical Abortion | Induced Abortion | Second Trimester Abortion | Health PersonnelEthiopia
-
Marie Stopes InternationalLondon School of Hygiene and Tropical Medicine; IpasCompletedContraception | Abortion | Post-abortionBangladesh
-
National University of MalaysiaRecruitingMedical; Abortion, Fetus | Missed Abortion | Incomplete AbortionMalaysia
-
IpasUnknownInduced Abortion | First Trimester AbortionNigeria
-
Boston UniversityCompletedAbortion, Induced | Abortion, Second TrimesterUnited States
-
Carmel Medical CenterUnknownMissed Abortion | Incomplete Abortion | Uterine Gestational Residua | Uterine Artery DopplerIsrael
-
Boston UniversityCompletedAbortion, Induced | Abortion, Second TrimesterUnited States
-
NHS LothianCompletedAbortion in First Trimester | Abortion EarlySweden, United Kingdom, France
Clinical Trials on Clindamycin
-
Phillip Brian SmithEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedSafety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (CLIN01)Obesity | Bacterial InfectionsUnited States
-
Taro Pharmaceuticals USACompletedAcne VulgarisUnited States
-
Alexandria UniversityNot yet recruitingInfection, BacterialEgypt
-
Akorn, Inc.CompletedAcne VulgarisUnited States, Belize
-
St. Luke's Hospital, PennsylvaniaCompletedPneumothorax | HemopneumothoraxUnited States
-
Lumara Health, Inc.CompletedVaginitis | VulvovaginitisUnited States, Russian Federation, Puerto Rico, India
-
United States Naval Medical Center, PortsmouthUnknown
-
Albert Schweitzer HospitalCompleted
-
Cairo UniversityUnknownSymptomatic Periapical Periodontitis
-
Aaron ChenJohns Hopkins University; Thrasher Research FundCompletedStaphylococcal Skin Infection | Abscess | Staphylococcal Infection | FolliculitisUnited States